Three Companies Run America's Prescription Drug Market

Express Scripts, CVS Caremark, and UnitedHealth's OptumRx collectively manage roughly 80% of all prescriptions filled in the United States, according to the Federal Trade Commission.

They are Pharmacy Benefit Managers — PBMs. The term sounds bureaucratic, but the business model isn't.

PBMs sit between your doctor's prescription and your pharmacist's counter. They negotiate with drug manufacturers, decide which drugs land on your insurance plan's approved list, and pocket the difference through a system of opaque "rebates." The FTC sued all three for using this system to artificially inflate drug prices at the direct expense of patients.

Diabetics. Seniors. Working families with no margin for error. Those are the people paying the premium.

What Express Scripts Agreed To Do

On February 6, 2026 — one day after President Trump signed new PBM reform legislation — the FTC reached a settlement with Express Scripts, Inc. and its affiliated entities, according to the House Committee on Energy and Commerce press release.

The terms are significant. Under the consent order, Express Scripts must:

• Base patient out-of-pocket costs on the actual net cost of a drug, not the artificially inflated list price
• Stop steering employers toward high-cost drug versions when cheaper, identical options exist
• Disclose payments to consultants who push employers toward pricier plans
• Provide drug-level data so plan sponsors can see what their members are actually being charged
• Participate in the Trump administration's TrumpRx direct-pricing program once regulatory changes are finalized
• Delink drug manufacturer compensation from list prices

FTC officials estimate these changes will drive down patient costs by $7 billion, according to Americans for Limited Government's reporting via Breitbart. Express Scripts also agreed to reshore its overseas purchasing operations, which the FTC says will return $750 billion in economic activity currently bouncing through foreign shell companies.

$750 billion routed offshore to avoid scrutiny and tax liability by a company managing Americans' prescription drugs.

CVS Caremark and OptumRx Are Running the Clock

CVS Caremark filed to pause its case for settlement discussions on March 23, according to Americans for Limited Government. OptumRx got another stay extension on April 13.

Both companies run the same playbook as Express Scripts — same inflated rebate model, same employer steering, same offshore shell structure. Their legal teams know the FTC has the evidence. So they're betting that public attention fades, that the news cycle moves on, and that they can negotiate something softer behind closed doors.

FTC Chairman Andrew Ferguson has been direct about this. The day after the Express Scripts settlement, he stood up an agency-wide Healthcare Task Force targeting consolidation-driven price increases, access problems, and reduced innovation across healthcare markets. In May, FTC Consumer Protection Director Chris Mufarrige publicly called out PBM schemes for endangering both consumer protection and market competition.

The agency has stated its case clearly. Now it needs to close it.

What Mainstream Coverage Is Getting Wrong

Most mainstream outlets treated the Express Scripts settlement as a one-day story — a press release win for the Trump administration. Then they moved on.

The Express Scripts deal is the opening move, not the finale. CVS Caremark is a $370 billion company. OptumRx is part of UnitedHealth Group, which posted over $22 billion in profit in 2023 alone, according to UnitedHealth's own earnings reports. These are not companies that settle out of goodwill. They settle when it costs more to fight than to comply.

Whether the FTC holds the line or quietly lets CVS and OptumRx negotiate their way into a weaker deal remains unclear. That question isn't getting adequate scrutiny from either left-leaning outlets that might credit the reform while ignoring the stall, or right-leaning outlets that declare victory before the job is done.

Chairman Brett Guthrie of the House Energy and Commerce Committee called this "just the beginning" in his February 6 statement. He's right.

This Is Taxpayer and Consumer Money

This isn't abstract policy. If you have health insurance through an employer, a PBM is almost certainly managing your drug benefits. If you've ever hit a high deductible on a medication your doctor prescribed, a PBM pricing scheme may be why.

The $7 billion in estimated patient savings from the Express Scripts settlement alone tells you the scale of the extraction. Multiply that across two more companies running identical systems and you're looking at tens of billions of dollars drained annually from patients, employers, and taxpayers — redirected to middlemen who produce nothing, manufacture nothing, and heal nobody.

The FTC under Chairman Andrew Ferguson has done real work here.

But CVS Caremark and OptumRx are stalling because stalling works — until it doesn't. The FTC needs to end the extensions, reject any settlement that doesn't match the Express Scripts terms, and make clear that the clock ran out.

Two companies. Same scheme. Same evidence. Same answer.